Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis

Jae Sung Kim, Jeffrey S. Kroin, Asokumar Buvanendran, Xin Li, Andre J van Wijnen, Kenneth J. Tuman, Hee Jeong Im

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective Osteoarthritic (OA) degeneration of the lumbar facet joints has been implicated in low back pain. This study was undertaken to investigate the biologic links between cellular and structural alterations within facet joint components and the development of symptomatic chronic back pain. Methods We generated an animal model of facet joint degeneration by intraarticular injection of monosodium iodoacetate (MIA) into facet joints (L3-L4, L4-L5, L5-L6) of Sprague-Dawley rats. Pain sensation due to pressure, which mimics a mechanical stimulus for facet joint injury, was measured using an algometer. Pain response was also assessed in a straight leg raising test. Cartilage alterations were assessed by biochemical evaluation and microfocal computed tomography (micro-CT). Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents was investigated. Results MIA injection resulted in severely damaged facet joint cartilage, proteoglycan loss, and alterations of subchondral bone structure. Micro-CT analyses suggested that the behavioral hyperalgesia from facet joint degeneration was not associated with foraminal stenosis. The biologic and structural changes in facet joints were closely associated with sustained and robust chronic pain. Morphine and pregabalin markedly alleviated pressure hyperalgesia, while celecoxib (a selective inhibitor of cyclooxygenase 2 [COX-2]) produced moderate antihyperalgesic effects and the effect of ketorolac (an inhibitor of COX-1 and COX-2) was negligible. Conclusion Our findings demonstrate that MIA injection provides a useful model for the study of OA changes in the facet joint and indicate that facet joint degeneration is a major cause of chronic low back pain. The treatment results suggest that classes of drugs that are widely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited efficacy once joint destruction is complete.

Original languageEnglish (US)
Pages (from-to)2966-2973
Number of pages8
JournalArthritis and Rheumatism
Volume63
Issue number10
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Zygapophyseal Joint
Back Pain
Osteoarthritis
Animal Models
Iodoacetates
Cyclooxygenase 2 Inhibitors
Therapeutics
Celecoxib
Hyperalgesia
Low Back Pain
Chronic Pain
Cartilage
Ketorolac
Pressure
Pain
Intra-Articular Injections
Injections
Arthralgia
Proteoglycans
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Kim, J. S., Kroin, J. S., Buvanendran, A., Li, X., van Wijnen, A. J., Tuman, K. J., & Im, H. J. (2011). Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis. Arthritis and Rheumatism, 63(10), 2966-2973. https://doi.org/10.1002/art.30487

Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis. / Kim, Jae Sung; Kroin, Jeffrey S.; Buvanendran, Asokumar; Li, Xin; van Wijnen, Andre J; Tuman, Kenneth J.; Im, Hee Jeong.

In: Arthritis and Rheumatism, Vol. 63, No. 10, 10.2011, p. 2966-2973.

Research output: Contribution to journalArticle

Kim, JS, Kroin, JS, Buvanendran, A, Li, X, van Wijnen, AJ, Tuman, KJ & Im, HJ 2011, 'Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis', Arthritis and Rheumatism, vol. 63, no. 10, pp. 2966-2973. https://doi.org/10.1002/art.30487
Kim, Jae Sung ; Kroin, Jeffrey S. ; Buvanendran, Asokumar ; Li, Xin ; van Wijnen, Andre J ; Tuman, Kenneth J. ; Im, Hee Jeong. / Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis. In: Arthritis and Rheumatism. 2011 ; Vol. 63, No. 10. pp. 2966-2973.
@article{7c3615b8f1d147cfaa4180238693f54c,
title = "Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis",
abstract = "Objective Osteoarthritic (OA) degeneration of the lumbar facet joints has been implicated in low back pain. This study was undertaken to investigate the biologic links between cellular and structural alterations within facet joint components and the development of symptomatic chronic back pain. Methods We generated an animal model of facet joint degeneration by intraarticular injection of monosodium iodoacetate (MIA) into facet joints (L3-L4, L4-L5, L5-L6) of Sprague-Dawley rats. Pain sensation due to pressure, which mimics a mechanical stimulus for facet joint injury, was measured using an algometer. Pain response was also assessed in a straight leg raising test. Cartilage alterations were assessed by biochemical evaluation and microfocal computed tomography (micro-CT). Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents was investigated. Results MIA injection resulted in severely damaged facet joint cartilage, proteoglycan loss, and alterations of subchondral bone structure. Micro-CT analyses suggested that the behavioral hyperalgesia from facet joint degeneration was not associated with foraminal stenosis. The biologic and structural changes in facet joints were closely associated with sustained and robust chronic pain. Morphine and pregabalin markedly alleviated pressure hyperalgesia, while celecoxib (a selective inhibitor of cyclooxygenase 2 [COX-2]) produced moderate antihyperalgesic effects and the effect of ketorolac (an inhibitor of COX-1 and COX-2) was negligible. Conclusion Our findings demonstrate that MIA injection provides a useful model for the study of OA changes in the facet joint and indicate that facet joint degeneration is a major cause of chronic low back pain. The treatment results suggest that classes of drugs that are widely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited efficacy once joint destruction is complete.",
author = "Kim, {Jae Sung} and Kroin, {Jeffrey S.} and Asokumar Buvanendran and Xin Li and {van Wijnen}, {Andre J} and Tuman, {Kenneth J.} and Im, {Hee Jeong}",
year = "2011",
month = "10",
doi = "10.1002/art.30487",
language = "English (US)",
volume = "63",
pages = "2966--2973",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis

AU - Kim, Jae Sung

AU - Kroin, Jeffrey S.

AU - Buvanendran, Asokumar

AU - Li, Xin

AU - van Wijnen, Andre J

AU - Tuman, Kenneth J.

AU - Im, Hee Jeong

PY - 2011/10

Y1 - 2011/10

N2 - Objective Osteoarthritic (OA) degeneration of the lumbar facet joints has been implicated in low back pain. This study was undertaken to investigate the biologic links between cellular and structural alterations within facet joint components and the development of symptomatic chronic back pain. Methods We generated an animal model of facet joint degeneration by intraarticular injection of monosodium iodoacetate (MIA) into facet joints (L3-L4, L4-L5, L5-L6) of Sprague-Dawley rats. Pain sensation due to pressure, which mimics a mechanical stimulus for facet joint injury, was measured using an algometer. Pain response was also assessed in a straight leg raising test. Cartilage alterations were assessed by biochemical evaluation and microfocal computed tomography (micro-CT). Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents was investigated. Results MIA injection resulted in severely damaged facet joint cartilage, proteoglycan loss, and alterations of subchondral bone structure. Micro-CT analyses suggested that the behavioral hyperalgesia from facet joint degeneration was not associated with foraminal stenosis. The biologic and structural changes in facet joints were closely associated with sustained and robust chronic pain. Morphine and pregabalin markedly alleviated pressure hyperalgesia, while celecoxib (a selective inhibitor of cyclooxygenase 2 [COX-2]) produced moderate antihyperalgesic effects and the effect of ketorolac (an inhibitor of COX-1 and COX-2) was negligible. Conclusion Our findings demonstrate that MIA injection provides a useful model for the study of OA changes in the facet joint and indicate that facet joint degeneration is a major cause of chronic low back pain. The treatment results suggest that classes of drugs that are widely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited efficacy once joint destruction is complete.

AB - Objective Osteoarthritic (OA) degeneration of the lumbar facet joints has been implicated in low back pain. This study was undertaken to investigate the biologic links between cellular and structural alterations within facet joint components and the development of symptomatic chronic back pain. Methods We generated an animal model of facet joint degeneration by intraarticular injection of monosodium iodoacetate (MIA) into facet joints (L3-L4, L4-L5, L5-L6) of Sprague-Dawley rats. Pain sensation due to pressure, which mimics a mechanical stimulus for facet joint injury, was measured using an algometer. Pain response was also assessed in a straight leg raising test. Cartilage alterations were assessed by biochemical evaluation and microfocal computed tomography (micro-CT). Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents was investigated. Results MIA injection resulted in severely damaged facet joint cartilage, proteoglycan loss, and alterations of subchondral bone structure. Micro-CT analyses suggested that the behavioral hyperalgesia from facet joint degeneration was not associated with foraminal stenosis. The biologic and structural changes in facet joints were closely associated with sustained and robust chronic pain. Morphine and pregabalin markedly alleviated pressure hyperalgesia, while celecoxib (a selective inhibitor of cyclooxygenase 2 [COX-2]) produced moderate antihyperalgesic effects and the effect of ketorolac (an inhibitor of COX-1 and COX-2) was negligible. Conclusion Our findings demonstrate that MIA injection provides a useful model for the study of OA changes in the facet joint and indicate that facet joint degeneration is a major cause of chronic low back pain. The treatment results suggest that classes of drugs that are widely used to treat OA, such as nonsteroidal antiinflammatory drugs, may have limited efficacy once joint destruction is complete.

UR - http://www.scopus.com/inward/record.url?scp=80053468028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053468028&partnerID=8YFLogxK

U2 - 10.1002/art.30487

DO - 10.1002/art.30487

M3 - Article

VL - 63

SP - 2966

EP - 2973

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -